Jade Biosciences is a clinical-stage biotechnology company focused on developing best-in-class therapies that address critical unmet needs in autoimmune diseases. Jade’s lead candidate, JADE101, targets the cytokine APRIL, and is currently being evaluated in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. Jade’s pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, as well as JADE301, an undisclosed antibody candidate, both currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. For more information, visit JadeBiosciences.com and follow the Company on LinkedIn.
Oui — Jade Biosciences a actuellement 7 offres ouvertes sur JobsRadar, réparties sur 12 services et 4 sites. 2 d’entre elles ont été publiées ces 30 derniers jours. 6 d’entre elles indiquent le salaire, avec une médiane de $205,000 par an et la plupart des offres entre $182,500 et $266,875. Dernière mise à jour le 8 septembre 2026 à 13:25 UTC.